Neurocrine HR chief gets 3,587-share award

NBIX’s Chief Human Resources Officer had PRSUs vest into shares, with part of the award withheld to cover taxes and no open-market sales reported.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Human Resources Officer Julie Cooke received a grant/award of 3,587 shares of Common Stock on September 11, 2026 upon certification of a performance metric for previously granted performance restricted stock units (PRSUs). On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on the PRSU vesting at a value of $156.22 per share; no shares were sold in the market. The filing notes that 21,985 of the reported shares are held by the Cooke Family Trust of 2004, over which Julie Cooke has voting and investment power, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cooke Julie

Role Chief Human Resources Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	3,587	$0.00	$0.00
Tax Withholding	Common Stock F2, F3	1,936	$156.22	$302K

Holdings After Transaction: Common Stock — 24,025 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
3. F3. 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Key Figures

Shares acquired from PRSU vesting: 3,587 shares Shares withheld for tax withholding requirements: 1,936 shares Per-share value for tax withholding: $156.22 per share +1 more

4 metrics

Shares acquired from PRSU vesting 3,587 shares Common Stock issued to Julie Cooke upon achievement of a PRSU performance metric on September 11, 2026

Shares withheld for tax withholding requirements 1,936 shares Withheld by Neurocrine Biosciences, Inc. on September 11, 2026 to satisfy tax on PRSU vesting

Per-share value for tax withholding $156.22 per share Value used for the 1,936 shares withheld to satisfy tax withholding requirements

Shares held by Cooke Family Trust 21,985 shares Reported as held by the Cooke Family Trust of 2004, with Julie Cooke having voting and investment power

Key Terms

performance restricted stock units (PRSUs), tax withholding requirements, voting and investment power

3 terms

performance restricted stock units (PRSUs) financial

"was previously granted performance restricted stock units (PRSUs) that vest upon"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

voting and investment power financial

"of which the Reporting Person has voting and investment power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award did NBIX executive Julie Cooke receive on September 11, 2026?

Julie Cooke received 3,587 shares of NBIX Common Stock on September 11, 2026, issued upon the achievement and certification of a performance metric tied to previously granted performance restricted stock units (PRSUs).

How many NBIX shares were withheld for taxes from Julie Cooke’s PRSU vesting?

To satisfy tax withholding requirements on the PRSU vesting, 1,936 NBIX shares were withheld by Neurocrine Biosciences, Inc. at a value of $156.22 per share, and the filing states that no shares were sold.

Were any of Julie Cooke’s NBIX transactions under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is marked in a way that indicates no Rule 10b5-1 trading plan is reported for these September 11, 2026 transactions.

How many NBIX shares are held through the Cooke Family Trust?

The filing states that 21,985 of the reported shares are held by the Cooke Family Trust of 2004, and that Julie Cooke has voting and investment power over these shares.

Did Julie Cooke sell any NBIX shares in the market in this Form 4?

No. The filing explains that the 1,936 shares reported with transaction code F were withheld to satisfy tax withholding requirements on PRSU vesting and that no shares were sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:04 PM Accepted by SEC EDGAR 09/15/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooke Julie

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		3,587	A	$0	25,961	D
Common Stock	09/11/2026		F(2)		1,936	D	$156.22	24,025(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

3. 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)